PASG
Passage Bio, Inc. Common StockstockNASDAQ
passage bio, inc., a genetic medicines company, develops transformative therapies for rare monogenic central nervous system (cns) diseases. the company develops pbgm01, which utilizes a proprietary, aavhu68 capsid to deliver to the brain and peripheral tissues a functional glb1 gene encoding lysosomal acid beta-galactosidase (ã-gal) for infantile gm1; pbft02, which utilizes an aav1 capsid to deliver to the brain a functional granulin, or grn, gene encoding progranulin for the treatment of ftd caused by a deficiency of progranulin; and pbkr03, which utilizes a proprietary, aavhu68 capsid to deliver to the brain and peripheral tissues a functional galc gene encoding the hydrolytic enzyme galactosylceramidase, for infantile krabbe disease. it has a strategic research collaboration with the trustees of the university of pennsylvania's gene therapy program; and collaboration agreement, and a development services and clinical supply agreement with catalent maryland, inc. the company was fou
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 4.00 | 2026-11-11 | +0.25% | 3.709 |
| 1M | 3.58 | 2026-10-19 | +12.01% | 0.020 |
| 3M | 4.52 | 2026-08-18 | -11.28% | 0.145 |
| 6M | 5.12 | 2026-05-18 | -21.68% | 0.562 |
| 1Y | 8.52 | 2025-11-18 | -52.93% | 2.031 |
| 2Y | 9.42 | 2024-11-18 | -57.43% | — |
| 5Y | 164.00 | 2021-11-18 | -97.56% | 1.610 |
Passage Bio, Inc. Common Stock (NASDAQ:PASG) stock price today is $4.01, and today's volume is 14,526. PASG is down 4.976% today. The 30 day average volume is 17,286. PASG market cap is $12.90M with 3.22M shares outstanding.